lunes, 29 de abril de 2024

Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial

Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00100-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_escmid24&_hsenc=p2ANqtz--4r5GZJoG_S5W8LSCF9-Z_VmqVnPbm2L1ckmADqp1OvtbiLYHuo0YwgqIBOmpyhGrUOTdyBxetM48qPdHzT32_8bZ5Ug&_hsmi=304768937&utm_content=304768937&utm_source=hs_email Lessons for dengue vaccines from a human challenge study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00153-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_escmid24&_hsenc=p2ANqtz--VpNFaSSQStywbrJbr6Ct7a3Xmq42ch4wxKTRsLbr_8tk6f7NhaU9UYboDbanG0CNqwwLasQIFrjVjQW8dD7ESwS6uyw&_hsmi=304768937&utm_content=304768937&utm_source=hs_email

No hay comentarios:

Publicar un comentario